Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Some breast cancer drugs can penetrate the blood-brain barrier (BBB), but they have not been very effective against brain metastases, whereas other, more effective anti-breast cancer drugs cannot penetrate the BBB at all. In a study published in the Journal of the National Cancer Institute, researchers used a new approach to selectively permeabilize the BBB at sites of brain metastases, even those 200 times smaller than currently detectable in the clinic.
To facilitate drug delivery to brain metastases, John Connell of the CRUK/MRC Gray Institute for Radiation Oncology and Biology, Churchill Hospital, Oxford, UK, and colleagues utilized the human pro-inflammatory cytokine, tumor necrosis factor (TNF), which they had previously shown could disrupt the BBB in rat brains.
The researchers first verified the expression of TNF receptors in mouse as well as human brain metastases by immunohistochemistry. They then induced brain metastases in mice by injection of mouse breast carcinoma cells labeled with green fluorescent protein. After metastases were detected by MRI, the researchers injected the mice with TNF or its analog, lymphotoxin (LT) and 2-24 hours later, the radiolabeled anti-breast cancer drug, trastuzumab.
Radiolabeled trastuzumab was detected at the cerebral metastases in mouse brains that had been treated with TNF, whereas the drug was excluded from metastases in control mice treated with saline solution. The same effect was observed in brain metastases of mice injected with human breast cancer cells. Importantly, BBB permeability lasted long enough to allow delivery of the drug, peaking at 6 hours and lasting 24 hours.
The authors conclude that the work represents "...a novel approach to facilitating the delivery of therapeutic and diagnostic agents to cerebral metastases by exploiting a previously unknown phenotype of the vasculature of brain metastases." Connell et al. note, however, that although TNF was effective in mice, variability in TNF receptors in humans could have different effects and that this new technique must be validated in clinical trials.
John J. Connell, Grégoire Chatain, Bart Cornelissen, Katherine A. Vallis, Alastair Hamilton, Len Seymour, Daniel C. Anthony and Nicola R. Sibson. JNCI J Natl Cancer Inst (2013) doi: 10.1093/jnci/djt276 First published online: October 9, 2013
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Breast Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Journal of the National Cancer Institute. "Blood-brain barrier breached by anti-breast cancer drugs using new technique." Medical News Today. MediLexicon, Intl., 11 Oct. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/267255>
Journal of the National Cancer Institute. (2013, October 11). "Blood-brain barrier breached by anti-breast cancer drugs using new technique." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267255.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.